

Special Issue

Colon-Targeted Drug Delivery

Message from the Guest Editor

Colon-targeted drug delivery (CTDD) is achieved when a drug is prevented from being systemically absorbed and metabolized in the upper intestine, leading to delivery of a much greater amount of the intact drug to the large intestine. Compared with conventional drug delivery, colon-targeted delivery of a drug increases the concentration of the drug in the large intestine while reducing systemic absorption of the drug. Thus, CTDD should confer therapeutic and toxicological advantages for the treatment of colonic diseases such as inflammatory bowel disease. CTDD can also be utilized for chronotherapy and oral peptide therapy owing to the transit time to and low proteolytic activity in the large intestine. In addition, oral drug delivery systems aiming at sustained release of a drug in the GI tract can reach the large intestine, which affects the pharmacokinetics and therapeutic activity of the drug. This Special Issue welcomes any papers dealing with oral drug delivery system reaching the large intestine, including CTDD.

Guest Editor

Prof. Dr. Yunjin Jung

Laboratory of Biomedical Chemistry, College of Pharmacy, Pusan National University, Busan 609-735, Republic of Korea

Deadline for manuscript submissions

closed (10 November 2021)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/54789

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).